This Week in General Medicine — May 14, 2026

Welcome to This Week in General Medicine. This week we're covering 10 notable papers spanning cardiovascular updates, advances in immunology, and new data on prevention and screening. Let's dive in.

Cardiovascular Updates

First, in cardiovascular medicine, we have two important trials evaluating long-standing therapies. One looks at the optimal duration of dual antiplatelet therapy after bypass surgery, and the other revisits the role of digoxin in heart failure.

Starting with coronary artery bypass grafting, or CABG, a trial in the BMJ provides clear guidance on the duration of dual antiplatelet therapy, or DAPT [5]. Current practice often involves 12 months of DAPT, but this comes with a bleeding risk. This multicenter, double-blind trial randomized over 2,000 patients who had a CABG with at least one saphenous vein graft to either 12 months of DAPT with ticagrelor and aspirin, or just three months of DAPT followed by aspirin plus placebo.

Results

The primary non-inferiority outcome was saphenous vein graft occlusion at one year. The shorter, three-month DAPT course was indeed non-inferior to the 12-month course, with occlusion rates of 10.8% and 11.2%, respectively. For the key safety outcome, the three-month strategy was superior in reducing bleeding. Clinically significant bleeding occurred in 8.3% of the three-month group versus 13.2% of the 12-month group. This means you would only need to treat 21 patients with the shorter duration to prevent one bleeding event. There was no difference in major adverse cardiovascular events between the groups.

Conclusions

For patients undergoing CABG with a saphenous vein graft, a three-month course of DAPT with ticagrelor and aspirin offers the same protection against graft occlusion as a 12-month course, but with a significantly lower risk of bleeding. This is a clear win for a shorter, safer therapy duration.

Next, we turn to a trial that challenges the modern role of one of cardiology's oldest drugs. The DECISION trial, published in Nature Medicine, investigated whether low-dose digoxin has a place in contemporary management of heart failure with reduced or mildly reduced ejection fraction [7]. Investigators randomized 1,001 patients with symptomatic heart failure and an LVEF of 50% or less to either low-dose digoxin or placebo, on top of standard therapy. The goal was to maintain a low serum digoxin concentration.

The Study

The primary outcome was a composite of total worsening heart failure events and cardiovascular mortality. After a median follow-up of about three years, there was no statistically significant difference between the groups. The rate ratio was 0.81, favoring digoxin, but the 95% confidence interval crossed one, ranging from 0.61 to 1.07. Looking at the components, there were numerically fewer worsening heart failure events in the digoxin group, but this was not statistically significant. Cardiovascular mortality was nearly identical between groups. The drug was generally well-tolerated and safe.

Conclusions

Despite hopes that a low-dose strategy might prove beneficial, this rigorous trial shows that adding low-dose digoxin to modern heart failure therapy does not significantly reduce major clinical events. While not harmful, it doesn't provide the benefit sought, casting further doubt on its routine use in this population.

Advances in Immunology

Next, we turn to several papers exploring immunomodulation for conditions ranging from rheumatology to cancer and even pulmonary fibrosis.

First, for patients with dermatomyositis, a phase 3 trial in The New England Journal of Medicine offers a new therapeutic option [10]. This study evaluated brepocitinib, an oral inhibitor of TYK2 and JAK1. Over 240 adults with active dermatomyositis were randomized to receive 30 milligrams of brepocitinib, 15 milligrams of brepocitinib, or placebo daily for one year, in addition to their standard therapies.

Results

The primary endpoint was the Total Improvement Score at week 52, a composite measure of myositis activity. The 30-milligram dose of brepocitinib was significantly superior to placebo, with a mean score difference of 15.3 points. However, the lower 15-milligram dose did not meet the primary endpoint. Importantly, the 30-milligram dose also showed significant benefits across all nine key secondary endpoints, including improvements in skin disease, successful glucocorticoid tapering, and better physical function. The trade-off was a higher rate of serious infections, occurring in 10% of the high-dose group compared to just 1% in the placebo group.

Conclusions

For adults with refractory dermatomyositis, brepocitinib at a 30-milligram dose provides significant, multifaceted benefits, but clinicians must be vigilant for an increased risk of serious infections.

Staying in rheumatology, a paper in Nature Medicine addresses a key clinical question: can we prevent the progression from palindromic rheumatism to full-blown rheumatoid arthritis, or RA? [1]. Palindromic rheumatism is characterized by recurrent, brief attacks of arthritis. This open-label trial randomized 70 individuals with seropositive palindromic rheumatism to receive either abatacept or hydroxychloroquine for two years. The primary outcome was the development of RA.

Results

The results were striking. Over 24 months, only 20.6% of participants treated with abatacept progressed to RA, compared to 50.0% of those on hydroxychloroquine. This represents a risk difference of nearly 30%. Abatacept also led to a longer time to progression and was associated with reduced intensity of joint attacks and a higher rate of remission. Both drugs were well tolerated.

Conclusions

In patients with high-risk, seropositive palindromic rheumatism, two years of treatment with abatacept is significantly more effective than hydroxychloroquine at preventing the evolution to established rheumatoid arthritis. This could represent a paradigm shift toward earlier, more aggressive intervention in this pre-RA state.

Finally in this section, two translational studies point to exciting future therapeutic avenues by targeting the cellular ecosystem of disease. A study in Science Translational Medicine focuses on idiopathic pulmonary fibrosis, or IPF [4]. Researchers found that senescent fibroblasts, which drive fibrosis, protect themselves from immune clearance. They do this by expressing a ligand called HLA-E, which engages the inhibitory NKG2A receptor on natural killer, or NK, cells, effectively putting them to sleep. In a mouse model, blocking this NKG2A receptor restored NK cell function, cleared the senescent fibroblasts, and promoted resolution of fibrosis. A clinical-grade NKG2A inhibitor, monalizumab, was shown to reactivate patient-derived NK cells in vitro.

In parallel, a study in Cell explored a new target for CAR T-cell therapy in solid tumors [9]. The team identified a receptor called uPAR that is broadly expressed on cancer cells in many common solid tumors, as well as on the supportive stromal cells that create a pro-fibrotic niche. They engineered uPAR-directed CAR T-cells which, in mouse models, were able to eliminate both the tumor cells and their stromal support system. This led to durable tumor regressions and eradication of metastases across diverse cancer types, without causing major toxicity. Both studies highlight a sophisticated strategy: targeting not just the 'bad' cell, but also the local environment that protects it, opening up new possibilities for treating fibrosis and solid cancers.

Prevention and Screening

Our final theme covers prevention and screening, with new data on COVID-19, postpartum hemorrhage, and colorectal cancer.

First, with COVID-19 still circulating, effective post-exposure prophylaxis remains a priority. A trial in The New England Journal of Medicine evaluated ensitrelvir, an oral protease inhibitor, for this purpose [3]. Investigators randomized nearly 2,000 household contacts of a person with COVID-19 to receive either ensitrelvir or placebo for five days, starting within 72 hours of the index patient's symptom onset.

Results

Ensitrelvir was highly effective. The primary endpoint—developing symptomatic, lab-confirmed COVID-19—occurred in just 2.9% of the ensitrelvir group, compared to 9.0% of the placebo group. This corresponds to a risk ratio of 0.33, meaning the drug cut the risk of developing COVID-19 by about two-thirds. Adverse events were similar between the groups.

Conclusions

For household contacts of a patient with COVID-19, a five-day course of ensitrelvir is an effective and safe prophylactic strategy to prevent infection and illness.

Next, in obstetrics, a large trial in the BMJ assessed prophylactic tranexamic acid, or TXA, for preventing postpartum hemorrhage in women with placenta previa undergoing cesarean delivery [2]. This is a very high-risk group. Nearly 1,700 women were randomized to receive either one gram of intravenous TXA or placebo shortly after umbilical cord clamping, in addition to standard prophylactic oxytocin.

Results

The primary outcome was postpartum hemorrhage, defined as blood loss of 1000 mL or more, or the need for a red cell transfusion. The primary outcome occurred in 29.7% of the TXA group versus 35.1% of the placebo group. This reduction was statistically significant, with a relative risk of 0.85, but the absolute benefit was modest. Importantly, there was no increase in serious adverse events like thromboembolism.

Conclusions

In women with placenta previa undergoing C-section, prophylactic TXA provides a statistically significant, though modest, reduction in postpartum hemorrhage without an apparent increase in harm. This supports its use as an additional safety measure in this high-risk setting.

Finally, we have the much-anticipated long-term follow-up of the NordICC trial, published in The Lancet [8]. This population-based randomized trial compared an invitation to colonoscopy screening versus no screening in over 84,000 people across Europe. We now have results at 13 years of follow-up.

Results

In the intention-to-screen analysis, which compares everyone randomized regardless of whether they got the colonoscopy, the invitation to screening significantly reduced the incidence of colorectal cancer. The risk ratio was 0.81. The benefit was driven by a reduction in distal, but not proximal, colorectal cancer. When looking only at those who actually underwent screening in a per-protocol analysis, the risk reduction for cancer incidence was much larger, with a risk ratio of 0.55.

However, for the crucial outcome of colorectal cancer mortality, the intention-to-screen analysis did not show a statistically significant benefit. The risk ratio was 0.88, but the 95% confidence interval ranged from 0.68 to 1.08. The authors note that the overall mortality from colorectal cancer in the control group was substantially lower than they had anticipated when designing the trial, which reduced their statistical power to detect a difference.

Conclusions

After 13 years, an invitation to a single colonoscopy significantly reduces the incidence of colorectal cancer, but a mortality benefit has not yet been demonstrated in the intention-to-screen analysis. The large difference between intention-to-screen and per-protocol results highlights that the effectiveness of a screening program is highly dependent on uptake. These findings will continue to fuel the debate on the optimal strategies for colorectal cancer screening.

We'll also briefly mention a new guidance document from the GRADE Working Group, published in Annals of Internal Medicine [6]. It provides a formal framework for guideline developers to incorporate planetary health considerations—such as the environmental impact of interventions—into their evidence-to-decision process. This is a crucial step towards making health care more sustainable.

Editor's Pick

If you only have time for one paper this week, make it the trial on DAPT duration after CABG from the BMJ [5]. The finding that three months of dual antiplatelet therapy is as effective as 12 months for preventing saphenous vein graft occlusion, while being significantly safer, is immediately practice-changing and offers a clear path to de-escalate therapy and reduce harm for a large patient population.

Clinical Bottom Line

Here are the key takeaways from this week in General Medicine:

First, for post-CABG patients with saphenous vein grafts, three months of dual antiplatelet therapy is non-inferior to 12 months for preventing graft occlusion and significantly reduces bleeding risk [5].

Second, in a negative trial, low-dose digoxin did not significantly reduce worsening heart failure events or cardiovascular mortality in patients with HFrEF or HFmrEF when added to modern therapy [7].

Third, in rheumatology, abatacept proved superior to hydroxychloroquine for preventing progression from seropositive palindromic rheumatism to rheumatoid arthritis [1], and the JAK inhibitor brepocitinib is an effective new option for refractory dermatomyositis, albeit with an increased infection risk [10].

Fourth, for prevention, ensitrelvir effectively reduces the risk of COVID-19 in household contacts after exposure [3], and prophylactic tranexamic acid offers a modest benefit in reducing postpartum hemorrhage for women with placenta previa undergoing C-section [2].

And finally, 13-year follow-up of the NordICC trial shows that an invitation to colonoscopy screening reduces colorectal cancer incidence but has not yet shown a statistically significant reduction in mortality in an intention-to-screen analysis, highlighting the impact of screening uptake [8].

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.